Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAT: BPS-314d-MR as add-on to Tyvaso in PAH
NCT01908699Phase 3Completed
- Sponsor
- Lung Biotechnology PBC
- Start
- May 2013
- Primary completion
- Feb 2019
- Countries
- 2
01
Overview
A Phase 3 trial of esuberaprost in pulmonary arterial hypertension (PAH), sponsored by Lung Biotechnology PBC. Started May 2013; status: completed.
02
Drugs
esuberaprost
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01908699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01908699.